Shots:
- Gubra to receive ~ $253.4M as up front, development, and commercialization milestones
- The collaboration will combine Gubra’s peptide drug discovery capabilities with Bayer’s expertise to develop innovative medicines to treat cardiorenal diseases
- The collaboration also use Gubra’s streaMLine which is an ML based peptide drug discovery platform & is used for fast screening and identification of potent therapeutic peptide candidates
Click here to read full press release/ article | Ref: Gubra | Image: Crunchbase
The post Bayer Signs a License and Research Agreement with Gubra to Develop Novel Peptide Therapeutics for Cardiorenal Diseases first appeared on PharmaShots.
